Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumorsKarin Schreiber, Hans Schreiber, Ronald E. Cannon et al.|Oncogene|2004Cited by 45
Pharmacokinetic Differences Between a T Cell-Tolerizing and a T Cell-Activating PeptideSanne Weijzen, W. Martin Kast, Hans Schreiber et al.|The Journal of Immunology|2001Cited by 31
Atomic-level differences between brain parenchymal- and cerebrovascular-seeded Aβ fibrilsKathryn P. Scherpelz, Stephen C. Meredith, Joseph Orgel et al.|Scientific Reports|2021Cited by 14